A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 [axitinib] At Single Doses of 5 mg, 7 mg And 10 mg, And At Multiple Doses.

Trial Profile

A Phase 1 Study In Patients With Advanced Solid Tumor To Evaluate The Pharmacokinetics And Safety Of AG-013736 [axitinib] At Single Doses of 5 mg, 7 mg And 10 mg, And At Multiple Doses.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Mar 2017

At a glance

  • Drugs Axitinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 30 Apr 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top